All In Biotech

Drug Trial Radar · NCT01021813

A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients With Primary Insomnia

Last checked: Nov 19, 2026Latest source record: Sep 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 781 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

781

Actual

Start

Dec 10, 2009

Primary completion

May 17, 2011

Study completion Aug 1, 2011

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 30, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will establish the safety and tolerability of suvorexant (MK-4305) when administered for up to 14 months. Participants will be randomized to receive suvorexant or placebo for a 12-month double-blind (DB) Treatment Phase. Participants who complete the 12-month DB Treatment Phase will enter a 2-month DB Randomized Discontinuation Phase. At the time of initial randomization, participants assigned to receive suvorexant during the initial 12-month Treatment Phase will be simultaneously randomized, in a 1:1 ratio, to receive either suvorexant or placebo during the 2-month Randomized Discontinuation Phase. Participants randomized to receive placebo in the initial 12-month Treatment Phase will continue to receive placebo during the 2-month Randomized Discontinuation Phase. The first 3 nights of the Randomized Discontinuation Phase are referred to as the Run-Out Phase, and will assess rebound and withdrawal.

Conditions

  • Insomnia

Interventions

  • SuvorexantDrug

    Oral tablet (30 mg and 10 mg), administered daily before bedtime

  • Dose-matched Placebo to SuvorexantDrug

    Oral tablet, administered daily before bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs) During the Double-Blind (DB) Treatment PhaseTime frame: From the first day of study treatment up to 12 months
  2. Percentage of Participants Who Experienced Sleep Paralysis AEs During the DB Treatment PhaseTime frame: From the first day of study treatment up to 12 months
  3. Percentage of Participants Who Experienced Complex Sleep-related Behaviors AEs During the DB Treatment PhaseTime frame: From the first day of study treatment up to 12 months
  4. Percentage of Participants Who Experienced Falls AEs During the DB Treatment PhaseTime frame: From the first day of study treatment up to 12 months
  5. Percentage of Participants Who Experienced Suicidal Ideation and/or Behavior AEs During the DB Treatment PhaseTime frame: From the first day of study treatment up to 12 months
  6. Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs During the DB Treatment PhaseTime frame: From the first day of study treatment up to 12 months
  7. Percentage of Participants Who Experienced Selected AEs Associated With Potential for Abuse During the DB Treatment PhaseTime frame: From the first day of study treatment up to 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.